Table 1

Baseline and end of study characteristics of the study population

Baseline

End of study


Placebo (n = 74)

Supplemented (n = 74)

p-value

Placebo (n = 74)

Supplemented (n = 74)

p-value


Age (months)

35.2 ± 20

37.9 ± 20

0.72

-

-

-

Sex

-

Female

45.9%

48.6%

0.74

-

-

-

Antecedent

Reported children with fever episode on the previous year

78.30 (69–87.6)

89.20 (82.1–96.3)

0.041

-

-

-

Reported children with mosquito-net use on the previous night

52.7 (41.4–64.0)

56.7 (45.4–68.0)

0.62

-

-

-

Anthropometry

Weight-for-height Z- score <-2.0

-0.73 ± 2.8

-0.82 ± 1.4

0.58

-1.10 ± 2

-1.03 ± 1.3

0.80

Height-for-age Z- score <-2.0

-1.60 ± 2.3

-1.50 ± 2.0

0.77

-1.5 ± 2.4

-1.49 ± 1.7

0.97

Weight-for-height Z- score <-2.0 (%)

20.3 (11.2–29.4)

13.5 (5.7–21.3)

0.20

27.0 (17.0–37.0)

23.0 (13.5–32.5)

0.56

Height-for-age Z- score <-2.0 (%)

47.3 (36.0–58.6)

40.5 (29.3–51.7)

0.40

46.0 (34.7–57.3)

35.0 (24.2–45.8)

0.20

Hematology

Mean (SD) hemoglobin (g/dl)

9.4 ± 1.6

9.31 ± 2.3

0.75

10.21 ± 1.82

10.09 ± 1.97

0.70

Anemia ≤ 7.0 g/dl(%)

5.4 (0.4–10.5)

18.0 (9.3–26.7)

0.020

5.4 (0.4–10.5)

5.4 (0.4–10.5)

0.71

Malariometric indices

Positive P. falciparum

61.0 (51–72)

76.0 (66.-85)

0.052

57.5% (46.2–68.8)

42.0% (32.8–55.2)

0.048

Geometric mean density P. falciparum positive asexual forms/μl

1444 (923–2259)

1589 (1026–2459)

0.38

1945 (1155–3275)

1011 (647–1579)

0.85

Enlarged spleen

61.0% (51–72)

58.0% (47–69)

0.73

57.0% (46–68)

53.0% (42–64)

0.62


Mean ± SD or % (CI 95%)

p < 0.05

Zeba et al. Nutrition Journal 2008 7:7   doi:10.1186/1475-2891-7-7

Open Data